Lineage Cell Therapeutics Common Stock

Lineage Cell Therapeutics (LCTX) currently reports a common stock of $540M as of June 2026. That compares with $490M in the prior-year period — up 9.2% year over year. Use the charts on this page to explore Lineage Cell Therapeutics's common stock history and peer comparisons.

Lineage Cell Therapeutics's common stock increased from $490M to $540M — a 9.2% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lineage Cell Therapeutics reported $540M in common stock as of June 2026. That compares with $490M in the prior-year period — up 9.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $540M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lineage Cell Therapeutics, and consider following LCTX for alerts when major investors trade the stock.

Lineage Cell Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $540M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LCTX with unrelated industries.